|Bid||81.00 x 400|
|Ask||199,999.98 x 200|
|Day's Range||81.50 - 82.00|
|52 Week Range||0.60 - 82.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 21, 2018 - Mar 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||81.91|
SAINT-GENIS-POUILLY, France, Feb. 12, 2018-- Advanced Accelerator Applications S.A., a Novartis company and leader in nuclear medicine theragnostics, today announced that it has entered into an exclusive ...
Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all of ...
SAINT-GENIS-POUILLY, France, Feb. 01, 2018-- Advanced Accelerator Applications S.A., a Novartis company and a leader in nuclear medicine theragnostics, today announced that a subsidiary of Novartis AG, ...
First-in-class Therapy Demonstrated 79% Improvement in Progression Free Survival in NETTER-1 Phase 3 Study in Midgut NET Patients. LUTATHERA ® marks first FDA Approval for a Peptide Receptor Radionuclide ...
Buyouts are the order of the day in the biotechnology sector this week, with a couple of big-name acquisitions dominating market sentiment heading into the US open on Tuesday. Celgene Corporation (NASDAQ:CELG) leads the pack with its just reported acquisition of Juno Therapeutics Inc (NASDAQ:JUNO), while Novartis AG (NYSE:NVS) announced the successful completion of a […] The post Celgene, Novartis Both Report Billion Dollar Buyouts appeared first on Market Exclusive.
Transaction expands Novartis Oncology neuroendocrine tumor (NET) treatment portfolio and adds radiopharmaceutical technology platform Lutathera® (lutetium Lu 177 dotatate), with a US PDUFA date of January ...
Stocks that are expected to significantly grow their profitability in the future can add meaningful upside to your portfolio. Broadcom and Advanced Accelerator Applications are examples of many high-growth stocksRead More...
Stock Monitor: Advanced Accelerator Applications Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 07, 2017 / Active-Investors free earnings report on IDEXX Laboratories, Inc. (NASDAQ: IDXX ) ...
Basel, December 7, 2017 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws ...
IN THE NEWS Cryptocurrencies have taken the investment world by storm, as reflected by the strong rally in Bitcoin, the original cryptocurrency. From $968.23 at the end of 2016, Bitcoin has rallied to ...
Novartis (NOVN.S) has agreed to buy French-based Advanced Accelerator Applications (AAA) (AAAP.O) for $3.9 billion (2.99 billion pounds), giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs. The deal further strengthens the Swiss drugmaker's oncology business, already boosted by the 2015 acquisition of GlaxoSmithKline's (GSK.L) marketed cancer drugs and August's approval of a ground-breaking gene-modifying leukaemia treatment. The cash offer of $41 per ordinary share and $82 per American depositary share represents a 47 percent premium to AAA's price before media reports on Sept. 27 that Novartis was interested, the two companies said on Monday.
Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.
Advanced Accelerator (AAAP) was a big mover last session, as the company saw its shares more than 10% on the day amid huge volumes.
Advanced Accelerator Applications shares made a run early on Monday after it came public that Novartis plans to buy the company.